Anti-CCL2 (Carlumab)-SMCC-DM1 is an antibody-drug conjugate (ADC) consisting of the human-derived anti-CCL2 (chemokine ligand 2) antibody Carlumab linked to the cytotoxic microtubule inhibitor DM1 through the linker SMCC. The ADCs toxic molecule and linker component are SMCC-DM1. This compound is applicable in cancer research, particularly for studying prostate cancer.
